A carregar...
The Public Repository of Xenografts (ProXe) enables discovery and randomized phase II-like trials in mice
Over 90% of drugs with preclinical activity fail in human trials, largely due to insufficient efficacy. We hypothesized that adequately powered trials of patient-derived xenografts (PDX) in mice could efficiently define therapeutic activity across heterogeneous tumors. To address this hypothesis, we...
Na minha lista:
Publicado no: | Cancer Cell |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Formato: | Artigo |
Idioma: | Inglês |
Publicado em: |
2016
|
Assuntos: | |
Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5177991/ https://ncbi.nlm.nih.gov/pubmed/27070704 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ccell.2016.03.008 |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|